MedTrace Logo

Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts

NCT05652998 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-15

No results posted yet for this study

Summary

To compare the efficacy of intralesional injection of autologous plasma rich platelets and candida antigen in treatment of patients with plane warts .

Conditions

  • Plane Wart

Interventions

BIOLOGICAL

C. albicans antigen

a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.

OTHER

autologous PRP

patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.

OTHER

saline

patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Hassan M Ibrahim, Ass. Prof. · Faculty of Medicine - South Valley University

  • Mohamed A Ali, Prof. Dr. · Faculty of Medicine - Sohag University

  • Eisa M Hegazy, Ass. Prof. · Faculty of Medicine - South Valley University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2022-12-30
Completion
2023-04-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05652998 on ClinicalTrials.gov